Surgical Options for the Treatment of Breast Cancer


This case-based course reviews multidisciplinary care for breast cancer, with a focus on the role of surgery. Elements of preoperative evaluation are discussed, as well as decision-making in early breast cancer regarding type of surgery and indications for neoadjuvant therapy.

Learning Objectives

Upon participation in this activity, learners will be better able to:

  • Describe elements of initial evaluation of a patient with breast cancer and specialties that should be consulted
  • Discuss surgical options for patients with early breast cancer
  • Describe patients with early breast cancer who may benefit from neoadjuvant chemotherapy
  • Review contraindications for breast conservation and indications for bilateral mastectomy
  • Apply knowledge gained to improve surgical treatment planning for patients with early breast cancer


  • Judeen Andrews, PA-C
    Nebraska Medicine, Omaha, NE
  • Morton S. Kahlenberg, MD, FACS
    Surgical Oncology Associates of South Texas, San Antonio, TX

Disclosure of Relationships with Companies

Financial relationships reported by course faculty, planners, and reviewers. (F = Faculty, P = Planner, R = Reviewer)

All relationships are considered self-held and compensated unless otherwise noted. (I= Immediate Family Member; Inst= My Institution)

  • Judeen K. Andrews, PA-C (F): no relationships to disclose
  • Morton S. Kahlenberg, MD, FACS (F): Honoraria – Genentech; Consulting or Advisory Role – Genentech; Speakers’ Bureau – Genentech; Travel, Accommodations, Expenses – Genentech/Roche
  • Nathan M. Shumway, DO, FACP (P, R): no relationships to disclose
  • Tony Philip, FACP, MD (P): Consulting or Advisory Role – Novartis, Bayer, Foundation Medicine; Travel, Accommodations, Expenses – Bayer, Novartis
  • Todd Alan Pickard, PA-C, FASCO (P, R): no relationships to disclose
  • Rami Manochakian, MD (P): Consulting or Advisory Role – Takeda, Guardant Health, AstraZeneca, Novocure
  • Katherine Byar, APRN-NP (P): no relationships to disclose
  • Chandrajit Raut, MD (P): Honoraria – Novartis; Research Funding – Novartis (Inst); Travel, Accommodations, Expenses – Novartis

Disclaimer/Unlabeled Usage Statement

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and/or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions and adverse effects.

New content added regularly, don't miss out!

This site is intended for healthcare professionals in France, Germany, Italy, Japan and the United Kingdom only.

The selection of ASCO content on this site was made by the ASCO Publication and Education teams. Springer Healthcare selected the experts for interview. All content is made available solely for educational and informational purposes and personal use only.

© 2021 American Society of Clinical Oncology (ASCO®). All Rights Reserved.

This program is supported by an educational grant from Daiichi Sankyo and brought to you by Springer Healthcare | Contact Us | Privacy Policy

We'd love your feedback!

Before you go please let us have your feedback...